Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2021, Vol. 26 ›› Issue (4): 454-461.doi: 10.12092/j.issn.1009-2501.2021.04.014

Previous Articles     Next Articles

Research progress in clinical trials of targeted drugs for gastric cancer

Pazilaiti YASEN 1,2,3, YUAN Hao 2,3, LU Hong 2,3, ZHENG Ya 2,3, WANG Yuping 2,3, ZHOU Yongning 2,3   

  1. 1 First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu, China; 2 Department of Gastroenterology, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China; 3 Key Laboratory for Gastrointestinal Diseases of Gansu Province, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China 
  • Received:2020-11-17 Revised:2021-01-04 Online:2021-04-26 Published:2021-05-11

PDF (PC)

182

Abstract: In the past several years, chemotherapy, as the best treatment option for advanced gastric cancer, however, was associated with adverse events and high resistance rates. Recently, molecular targeted drugs have gradually come into notice of clinical researchers due to the advantages of selectively killing tumor cells and less adverse events. Many clinical trials have confirmed targeted drugs targeting receptor tyrosine kinases combined with chemotherapy drugs could provide more survival benefits and might be effective for the treatment of gastric cancer. This article aims to demonstrate the progress in clinical trials of targeted therapeutic drugs for gastric cancer.

Key words: gastric cancer, targeted therapeutic drugs, clinical trials

CLC Number: